Lurbinectedin, a medication used in the treatment of certain types of cancer, has been associated with potential risks to unborn babies. The drug is classified as Pregnancy Category D by the FDA, indicating evidence of fetal risk based on human data. It is advised that lurbinectedin should not be used during pregnancy unless the potential benefits outweigh the risks to the fetus. Additionally, it is recommended to use effective contraception during treatment with lurbinectedin and for at least six months after the last dose to prevent pregnancy due to the drug's potential harmful effects on unborn babies [2].

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf
[3] https://www.mayoclinic.org/drugs-supplements/lurbinectedin-intravenous-route/side-effects/drg-20490804?p=1